# A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma

> **NCT01145989** · PHASE2 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 8 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** AT9283

## Key facts

- **NCT ID:** NCT01145989
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02-15
- **Primary completion:** 2014-10-29
- **Final completion:** 2015-11-27
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2023-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01145989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01145989, "A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01145989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*